Orencia and Progressive multifocal leukoencephalopathy - a phase IV clinical study of FDA data

Summary:

Progressive multifocal leukoencephalopathy is reported as a side effect among people who take Orencia (abatacept), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Humira, and have Enthesopathy.

The phase IV clinical study analyzes which people have Progressive multifocal leukoencephalopathy when taking Orencia. It is created by eHealthMe based on reports of 135,080 people who have side effects when taking Orencia from the FDA, and is updated regularly.

What is Orencia?

Orencia has active ingredients of abatacept. It is often used in rheumatoid arthritis. eHealthMe is studying from 135,415 Orencia users. Check the latest studies of Orencia.

What is Progressive multifocal leukoencephalopathy?

Progressive multifocal leukoencephalopathy (rapidly progressive neuromuscular disease caused by opportunistic infection of brain cells) is found to be associated with 595 drugs and 921 conditions by eHealthMe. Check the latest studies of Progressive multifocal leukoencephalopathy.

On May, 06, 2026

135,080 people reported to have side effects when taking Orencia.
Among them, 34 people (0.03%) have Progressive multifocal leukoencephalopathy.

Could Orencia cause Progressive multifocal leukoencephalopathy?

Among these 34 people:

How long have people been on Orencia when they have Progressive multifocal leukoencephalopathy? *

What is the gender of people who have Progressive multifocal leukoencephalopathy when taking Orencia? *

female: 87.1 %
male: 12.9 %

What is the age of people who have Progressive multifocal leukoencephalopathy when taking Orencia? *

What are other drugs people take besides Orencia? *

What are other side effects people have besides Progressive multifocal leukoencephalopathy? *

Cardiac Tamponade (fluid accumulates in heart covering): 3 people, 8.82%
Pericarditis (inflammation of the pericardium): 3 people, 8.82%
Basal Cell Carcinoma (a skin cancer, it rarely metastasizes or kills): 2 people, 5.88%
Nasopharyngitis (inflammation of the nasopharynx): 2 people, 5.88%
Feeling Abnormal: 1 person, 2.94%
Cerebral Infarction (less blood supply to brain resulting tissue damage): 1 person, 2.94%
Confusional State: 1 person, 2.94%
Depression: 1 person, 2.94%
Disturbance In Attention: 1 person, 2.94%
Dizziness: 1 person, 2.94%

What are the existing conditions these people have? *

Tendonitis (a condition that causes pain and swelling of tendons): 2 people, 5.88%
Osteoporosis (bones weak and more likely to break): 2 people, 5.88%
Eosinophilia (eosinophil count in the peripheral blood exceeds): 2 people, 5.88%
Enthesopathy (disorder of entheses (bone attachments)): 2 people, 5.88%
Interstitial Lung Disease: 1 person, 2.94%

* Approximation only. Some reports may have incomplete information.

Do you take Orencia and have Progressive multifocal leukoencephalopathy?

- Check whether Progressive multifocal leukoencephalopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Orencia:

Orencia (135,415 reports)

Progressive multifocal leukoencephalopathy treatments and more:

Progressive multifocal leukoencephalopathy (13,731 reports)

How severe was Progressive multifocal leukoencephalopathy and when was it recovered:

Progressive multifocal leukoencephalopathy in Orencia

Expand to all the drugs that have ingredients of abatacept:

Progressive multifocal leukoencephalopathy and drugs with ingredients of abatacept (61 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Orencia:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Progressive multifocal leukoencephalopathy:

Progressive multifocal leukoencephalopathy (595 drugs)

Browse all the conditions that are associated with Progressive multifocal leukoencephalopathy:

Progressive multifocal leukoencephalopathy (921 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on abatacept (the active ingredients of Orencia) and Orencia (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.